Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries
Catalyst Pharm Inc
(NQ:
CPRX
)
19.87
-0.04 (-0.20%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Catalyst Pharm Inc
< Previous
1
2
3
4
5
6
7
8
9
Next >
Top 3 Health Care Stocks That May Crash In August
August 14, 2024
Via
Benzinga
The Latest Analyst Ratings For Catalyst Pharmaceuticals
August 12, 2024
Via
Benzinga
CPRX Stock Earnings: Catalyst Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024
August 07, 2024
CPRX stock results show that Catalyst Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via
InvestorPlace
Catalyst Pharmaceuticals Reports Strong Second Quarter 2024 Financial Results and Provides Corporate Update
August 07, 2024
From
Catalyst Pharmaceuticals, Inc.
Via
GlobeNewswire
Top 3 Health Care Stocks You May Want To Dump This Quarter
July 30, 2024
Via
Benzinga
A Closer Look at 7 Analyst Recommendations For Catalyst Pharmaceuticals
June 03, 2024
Via
Benzinga
Decoding 8 Analyst Evaluations For Catalyst Pharmaceuticals
May 10, 2024
Via
Benzinga
Decoding 7 Analyst Evaluations For Catalyst Pharmaceuticals
March 27, 2024
Via
Benzinga
Assessing Catalyst Pharmaceuticals: Insights From 4 Financial Analysts
March 07, 2024
Via
Benzinga
Vir Biotechnology Stock Reaches 80-Plus RS Rating Benchmark
July 26, 2024
On Friday, Vir Biotechnology stock had its Relative Strength (RS) Rating upgraded to 82, up from 64 a day earlier.
Via
Investor's Business Daily
Catalyst Pharmaceuticals Enters Into an Exclusive License, Supply and Commercialization Agreement with Kye Pharmaceuticals for AGAMREE® in Canada
July 24, 2024
From
Catalyst Pharmaceuticals, Inc.
Via
GlobeNewswire
Catalyst Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 7, 2024
July 22, 2024
The Company will Host a Conference Call and Webcast on Thursday, August 8, 2024, at 8:30 AM ET
From
Catalyst Pharmaceuticals, Inc.
Via
GlobeNewswire
Trading SMID Biotech Stocks In A Volatile Market
July 01, 2024
Trading SMID biotech stocks is difficult no matter what you know. Large cap biopharma with dividends should be the focus for non-traders. Healthcare and smaller caps are lagging within the context of a...
Via
Talk Markets
Catalyst Pharmaceuticals Receives U.S. FDA Approval For Increased Maximum Daily Dose For FIRDAPSE®
May 30, 2024
From
Catalyst Pharmaceuticals, Inc.
Via
GlobeNewswire
Catalyst Pharmaceuticals to Participate at the Jefferies Global Healthcare Conference 2024
May 28, 2024
From
Catalyst Pharmaceuticals, Inc.
Via
GlobeNewswire
2 Incredible Growth Stocks to Buy Hand Over Fist Right Now
May 15, 2024
These two healthcare stocks may be deeply undervalued.
Via
The Motley Fool
Catalyst Pharmaceuticals Stock Clears Technical Benchmark With 83 RS Rating
May 14, 2024
On Tuesday, Catalyst Pharmaceuticals stock hit a key technical milestone, with its Relative Strength Rating climbing to 83 from 79.
Via
Investor's Business Daily
Catalyst's New CEO Has Big Ideas For The Small Biotech
May 10, 2024
Richard Daly is Catalyst Pharmaceuticals' second CEO, taking over for Patrick McEnany, who retired last year.
Via
Investor's Business Daily
CPRX Stock Earnings: Catalyst Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024
May 08, 2024
CPRX stock results show that Catalyst Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Via
InvestorPlace
Top 10% Biotech Catalyst Pharma Slips On Mixed First-Quarter
May 08, 2024
The company doubled Wall Street's earnings views, but sales came in short.
Via
Investor's Business Daily
Catalyst Pharmaceuticals Reports Solid First Quarter 2024 Financial Results and Provides Business Update
May 08, 2024
From
Catalyst Pharmaceuticals, Inc.
Via
GlobeNewswire
Catalyst Pharmaceuticals to Participate at the BofA Securities Health Care Conference 2024
May 01, 2024
From
Catalyst Pharmaceuticals, Inc.
Via
GlobeNewswire
Catalyst Pharmaceuticals to Report First Quarter 2024 Financial Results on May 8, 2024
April 22, 2024
The Company will Host a Conference Call and Webcast on Thursday, May 9, 2024, at 8:30 AM ET
From
Catalyst Pharmaceuticals, Inc.
Via
GlobeNewswire
Catalyst Pharmaceuticals Announces Support for the Inaugural Lambert-Eaton Myasthenic Syndrome (LEMS) Awareness Day
March 28, 2024
From
Catalyst Pharmaceuticals, Inc.
Via
GlobeNewswire
Catalyst Pharmaceuticals to Participate in the 2024 Cantor Virtual Muscular Dystrophy Symposium
March 27, 2024
From
Catalyst Pharmaceuticals, Inc.
Via
GlobeNewswire
3 Strong Buy Biotech Stocks to Add to Your Q2 Must-Watch List
March 27, 2024
Don’t miss out on these three strong buy biotech stocks that are leaders to add to your portfolio for Q2 this year.
Via
InvestorPlace
7 Biotech Stocks Ready to Ride the Sector’s Resurgence
March 18, 2024
With investors seeking new opportunities with certain segments appearing stretched, biotech stocks offer a viable canvas.
Via
InvestorPlace
Madrigal Pharmaceuticals Stock Hits 80-Plus Relative Strength Rating Benchmark
March 18, 2024
On Monday, Madrigal Pharmaceuticals stock hit a key technical milestone, seeing its Relative Strength Rating jump to 83 from 69 a day ago.
Via
Investor's Business Daily
Catalyst Pharmaceuticals Announces AGAMREE® Now Commercially Available in the U.S. for the Treatment of Duchenne Muscular Dystrophy (DMD)
March 13, 2024
From
Catalyst Pharmaceuticals, Inc.
Via
GlobeNewswire
3 Sexy Small-Cap Stocks to Add Sizzle to Your Portfolio
March 10, 2024
While small-cap stocks can be incredibly risky, they also offer the potential for dramatic gains you won’t find with the big dogs.
Via
InvestorPlace
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.